ES2521674T3 - Métodos de tratamiento de hiperuricemia y estados patológicos asociados - Google Patents

Métodos de tratamiento de hiperuricemia y estados patológicos asociados Download PDF

Info

Publication number
ES2521674T3
ES2521674T3 ES09792556.4T ES09792556T ES2521674T3 ES 2521674 T3 ES2521674 T3 ES 2521674T3 ES 09792556 T ES09792556 T ES 09792556T ES 2521674 T3 ES2521674 T3 ES 2521674T3
Authority
ES
Spain
Prior art keywords
patient
hyperuricemia
treatment
methods
pathological conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09792556.4T
Other languages
English (en)
Inventor
Jesse Cedarbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transition Therapeutics Ireland Ltd
Original Assignee
Transition Therapeutics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transition Therapeutics Ireland Ltd filed Critical Transition Therapeutics Ireland Ltd
Application granted granted Critical
Publication of ES2521674T3 publication Critical patent/ES2521674T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Escilo-inositol para utilizar en un método para disminuir los niveles de ácido úrico de un paciente con necesidad del mismo en uno o más tejidos u órganos, sangre, suero, orina o combinaciones de los mismos, que comprende: administrar al paciente una cantidad eficaz de escilo-inositol para disminuir el nivel de ácido úrico en el paciente en comparación con el nivel de ácido úrico del paciente antes de la administración

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES09792556.4T 2008-09-15 2009-09-15 Métodos de tratamiento de hiperuricemia y estados patológicos asociados Active ES2521674T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9702308P 2008-09-15 2008-09-15
US97023P 2008-09-15
PCT/US2009/056985 WO2010031051A1 (en) 2008-09-15 2009-09-15 Methods of treatment of hyperuricemia and associated disease states

Publications (1)

Publication Number Publication Date
ES2521674T3 true ES2521674T3 (es) 2014-11-13

Family

ID=41319433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09792556.4T Active ES2521674T3 (es) 2008-09-15 2009-09-15 Métodos de tratamiento de hiperuricemia y estados patológicos asociados

Country Status (9)

Country Link
US (1) US8748496B2 (es)
EP (1) EP2349280B1 (es)
JP (1) JP5685192B2 (es)
AR (1) AR073514A1 (es)
AU (1) AU2009290612B2 (es)
CA (1) CA2737163C (es)
ES (1) ES2521674T3 (es)
TW (1) TW201016208A (es)
WO (2) WO2010031051A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
CA2604399A1 (en) 2005-04-11 2006-10-19 Savient Pharmaceuticals, Inc. Variant forms of urate oxidase and use thereof
US9377454B2 (en) 2009-06-25 2016-06-28 Crealta Pharmaceuticals Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN102726721A (zh) * 2011-12-21 2012-10-17 聂存良 一种平衡性的微量元素排铅口服液
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
CN109666687B (zh) * 2018-12-14 2020-08-04 艾美科健（中国）生物医药有限公司 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
JP2008520589A (ja) * 2004-11-17 2008-06-19 ジョアン マクローリン， シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
US20080200437A1 (en) * 2006-12-29 2008-08-21 Jean-Marie Lehn Cyclitols and Their Derivatives and Their Therapeutic Applications

Also Published As

Publication number Publication date
JP2012502914A (ja) 2012-02-02
WO2010031061A1 (en) 2010-03-18
EP2349280B1 (en) 2014-07-30
WO2010031051A1 (en) 2010-03-18
US8748496B2 (en) 2014-06-10
US20100152305A1 (en) 2010-06-17
AU2009290612A1 (en) 2010-03-18
CA2737163C (en) 2019-03-12
AU2009290612B2 (en) 2015-05-14
AR073514A1 (es) 2010-11-10
EP2349280A1 (en) 2011-08-03
JP5685192B2 (ja) 2015-03-18
CA2737163A1 (en) 2010-03-18
TW201016208A (en) 2010-05-01

Similar Documents

Publication Publication Date Title
ES2521674T3 (es) Métodos de tratamiento de hiperuricemia y estados patológicos asociados
Burton et al. Hypoxia-reoxygenation; a potential source of placental oxidative stress in normal pregnancy and preeclampsia
TR201818927T4 (tr) Kataterlerde İyileştirme
EA201070465A1 (ru) Устройство для управления потоком в органе тела
BRPI0610901A2 (pt) mÉtodo de uso de uma soluÇço aquosa de potencial oxi-redutivo em aplicaÇÕes dentais
CL2007003648A1 (es) Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
AR058749A1 (es) Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento
Morimatsu et al. Early and exclusive use of norepinephrine in septic shock
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
BR112017026660A2 (pt) composição e kit para tratamento de perda de fluidos que provocam hipotensão e/ou hipovolemia
ES2619569T3 (es) Método de ensayo de infección o inflamación de las vías respiratorias inferiores
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
RU2009139734A (ru) Способ прогнозирования сосудистых нарушений у больных с эссенциальной артериальной гипертонией
AR085837A1 (es) Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer
Mueller et al. Mandibular reconstruction with microvascular re-anastomosed fibular free flaps–Two complementary methods of postoperative transplant monitoring
Tanaka et al. Serum S100B is a useful surrogate marker for long-term outcomes in photochemically-induced thrombotic stroke rat models
AR049922A1 (es) Procedimientos para aumentar la cantidad de hueso
ES2599168T3 (es) Grelina para promover la recuperación de un animal en tratamiento médico
von Preussen et al. Acne inversa successfully treated with infliximab.
RU163270U1 (ru) Устройство для компрессионного гемостаза при внутрибрюшных кровотечениях
RU2011122721A (ru) Способ оптимизации лечения хронического миелолейкоза ингибиторами тирозинказы abl
Gray Impaired lymphatic clearance and pro-inflammatory cytokines in mechanically loaded tissue-implications in pressure ulcer aetiology
CN101745099A (zh) 高压静电芒刺苞电场糖尿病足贴